Novavax
NVAX
143 hedge funds and large institutions have $623M invested in Novavax in 2014 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 61 increasing their positions, 30 reducing their positions, and 15 closing their positions.
103% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 30
47% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 15
4% more funds holding
Funds holding: 137 → 143 (+6)
1% less capital invested
Capital invested by funds: $632M → $623M (-$8.62M)
68% less call options, than puts
Call options by funds: $3.1M | Put options by funds: $9.59M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$33.9M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$11.6M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$7.67M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$6.11M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$7.21M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.34M |
| 3 |
AGCJ
Alden Global Capital (Jersey)
St. Helier,
Jersey
|
-$6.03M |
| 4 |
Franklin Resources
San Mateo,
California
|
-$2.65M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.93M |
NVAX Hedge Fund Activity: Q3 2014 in Review
143 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2014, worth a combined $623M — down 1.4% from $632M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NVAX positions and 15 closed out — a net gain of 7 holders — while 61 added to existing stakes and 30 trimmed.
The largest buyer was BB Biotech, opening a new position worth an estimated $33.9M. The largest seller was RA Capital Management, cutting an estimated $7.21M.
- 143 institutional investors held Novavax (NVAX) as of Q3 2014, up from 137 in Q2 2014.
- Funds reported $623M of Novavax stock for Q3 2014, down 1.4% quarter-over-quarter.
- 22 funds opened new Novavax positions in Q3 2014 and 15 closed out, a net change of +7 holders.
- The largest Novavax buyer in Q3 2014 was BB Biotech, an estimated $33.9M added.
- The largest Novavax seller in Q3 2014 was RA Capital Management, an estimated $7.21M sold.
Based on aggregated 13F filings for Q3 2014.